Psychopharmacotherapy for addictive and comorbid disorders: Current studies

Journal of Addictive Diseases

Volumn 16, Issue 4, 1997, Pages 23-40

  Pechter, Bradley M ^a   Miller, Norman S ^b  

^a University of Illinois ^*  (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSTINENCE; ADDICTION; ARTICLE; COMORBIDITY; HUMAN; MENTAL DISEASE; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; TREATMENT PLANNING;

ALCOHOLISM; ANXIETY DISORDERS; CASE MANAGEMENT; COMBINED MODALITY THERAPY; DECISION TREES; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; MENTAL DISORDERS; MOOD DISORDERS; OPIOID-RELATED DISORDERS; PSYCHOTHERAPY; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 0030681336     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550889709511141     Document Type: Article

References (61)

1. MiHer NS, Gold MS. The psychiatrist’s role in integrating pharmacological and nonpharmacological treatments for addictive disorders. Psychiatric Annals. 1992;22(8):436-40.
2. Gold MS, Miller NS. Seeking drugs/alcohol and avoiding withdrawal. Psychiatric Annals. 1992;22(8):430-5.
3. Miller NS, Gold MS. A neurochemical model for alcohol and drug addiction. J Psychoactive Drugs. 1993;25(2): 121-8.
4. Miller NS. Issues in the diagnosis and treatment of comorbid addictive and other psychiatric disorders. Directions in Psychiatry. 1994;14(25):1-8.
5. Myers RD. New drugs for the treatment of experimental alcoholism. Alcohol. 1994; 11(6):439-51.
6. Batki SL. Drug abuse, psychiatric disorders, and AIDS: Dual and triple diagnosis. West J Med. 1990;152(5):547-52.
7. Adelman SA, Fletcher KE, Bahnassi A, et al. The scale for treatment integration of the dually diagnosed (ST1DD): An instrument for assessing intervention strategies in the pharmacotherapy of mentally ill substance abusers. Drug Alcohol Depend. 1991;27:35-42.
8. Adelman SA, Fletcher K.E, Bahnassi A. Pharmacotherapeutic management strategies for mentally ill substance abusers. J Subst Abuse Treat. 1993;10:353-8.
9. Minkoff K. An integrated treatment model for dual diagnosis of psychosis and addiction. Hospital and Community Psychiatry. 1989;40:1031-6.
10. Roman PM. Inpatient alcohol and drug treatment: a national study of treatment centers. Executive Report. Institute for Behavioral Research. University of Georgia. Supported by National Institute of Alcohol Abuse and Addiction. 1989; 1:22.
11. Dackis CA, Gold MS, Pottash ALC, et al. Evaluating depression in alcoholics. Psychiatry Res. 1986;17:105-9.
12. American Psychiatric Association: Diagnostic and statistical manual of mental disorders, 4th edition. Washington, D.C, American Psychiatric Association, 1994.
13. Merikangas KR, Leckman JF, Prusoff BA, et al. Familial transmission of depression and alcoholism. Arch Gen Psychiatry. 1985;42(4):367-72.
14. Brown SA, Inaba RK., Gillin JC, et al. Alcoholism and affective disorder: Clinical course of depressive symptoms. Am J Psychiatry. 1995;152:45-52.
15. Brady KT, Killeen T, Jarrell P. Depression in alcoholic schizophrenic patients. Am J Psychiatry. 1993;150:1255-6.
16. Ciraulo DA, Jaffe JH. Tricyclic antidepressants in the treatment of depression associated with alcoholism. J Clin Psychopharamacol. 1981;1:146-50.
17. Nunes EV, McGrath PJ, Quitkin FM, et al. Imipramine treatment of alcoholism with comorbid depression. Am J Psychiatry, 1993; 150(6):963-5.
18. Nunes EV, Quitkin FM, Brady R, et al. Imipramine treatment of methadone maintenance patients with affective disorder and illicit drug use. Am J Psychiatry. 1991;148(5):667-9.
19. Zicdonis DM, Kosten TR. Depression as prognostic factor for pharmacological treatment of cocaine dependence. Psychopharmacol Bull. 1991;27:337-43.
20. Gorelick DA. Serotonin uptake blockers and the treatment of alcoholism, ln Galanter M (ed): Recent developments in alcoholism, vol 7, pp. 267-81. New York, Plenum, 1989.
21. Gorelick DA, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res. 1992; 16(2):261-5.
22. Amit Z, Brown Z, Sutherland Z, et al. Reduction in alcohol intake in humans as a function of treatment with zimeldine: implications for treatment. In Naranjo CA, Sellers EM (eds): Research advances in new psychopharmacological treatments for alcoholism. Amsterdam, Excerpta Medica. 1985; 189-98.
23. Naranjo CA, Sellers EM, Jullivan JT, et al. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther. 1987;41:266-74.
24. Naranjo CA, Sellers EM, Roach CA, et al. Zimeldine-induced variations in alcohol intake by non-depressed heavy drinkers. Clin Pharmacol Ther. 1984; 35:374-81.
25. Winokur G, Cook B, Lisków B, et al. Alcoholism in manic depressive (bipolar) patients. J Stud Alcohol. 1993;54:574-6.
26. Sonne SC, Brady KT, Morton WA. Substance abuse and bipolar affective disorder. J Nerv Ment Dis. 1994; 182(6):349-52.
27. Dorus W, Ostrów DG, Anton R, et al. Lithium treatment of depressed and nondeprcssed alcoholics. JAMA. 1989;262:1646-52.
28. Fawcett J, Clark DC, Gibbons RD, et al. Evaluation of lithium therapy for alcoholism. J Clin Psychiatry. 1984;45:494-9.
29. Nagel K, Adler LE, Bell J, et al. Lithium carbonate and mood disorder in recently detoxified alcoholics: A double-blind, placebo-controlled pilot study. Alcohol Clin Exp Res. 1991;15(6):978-81.
30. Halikas J, Kuhn K, Carlsan G. The effect of carbamazepine on cocaine use. American Journal of Addictions. 1992; 1 (1):30-9.
31. Kosten TR, Gawin FH, Kosten TA, et al. Six month follow-up of short-term pharmacotherapy for cocaine dependence. American Journal of Addictions. 1992; 1(1):40-9.
32. Decker KP, Ries RK. Differential diagnosis and psychopharmacology of dual disorders. Psychiatr Clin North Am. 1993; 16(4):703-19.
33. Bowen RC, Cipywnyk D, D’Arcy C, et al. Alchoholism, anxiety disorders, and agoraphobia. Alcohol Clin Exp Res. 1984;8:48-50.
34. Smail P, Stockwell T, Canter S, et al. Alcohol dependence and phobic anxiety states I. A prevalence study. BrJ Psychiatry. 1984;144:53-7.
35. Reich J, Chaudhry D. Personality of panic disorder alcohol abusers. J Nerv Ment Dis. 1987;175:224-8.
36. Starcevic V, Uhlenhuth EH, Kellner R, et al. Comorbidity in panic disorder:II. Chronology of appearance and pathogenic comorbidity. Psychiatry Res. 1993;46:285-93.
37. George DT, Nutt DJ, Dwyer BA, et al. Alcoholism and panic disorder: Is the comorbidity more than coincidence? Acta Psychiatr Scand. 1990;81:97-107.
38. Janicak PG, Davis JM, Preskom SH, Ayd FJ Jr: Principles and practice of psychopharmacotherapy. Baltimore: Williams & Wilkins, 1993.
39. Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics: A placebo-controlled trial. Arch Gen Psychiatry. 1994;51:720-31.
40. Bowers MB, Mazure CM, Nelson JC, et al. Psychotogenic drug use and neuroleptic response. Schizophr Bull. 1990;6(1):81-5.
41. Buckley P, Thompson P, Way L, et al. Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy. Am J Psychiatry. 1994; 151 (3):385-9.
42. Rosenthal RN, Hellerstein DJ, Miner CR. Positive and negative syndrome typology in schizophrenic patients with psychoactive substance use disorders. Compr Psychiatry. 1994;35(2):91-8.
43. Ziedonis D, Richardson T, Lee E, et al. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull. 1992;28(3):309-14.
44. Gawin FH, Kleber HD, Byck R, et al. Desipramine facilitation in initial cocaine abstinence. Arch Gen Psychiatry. 1989;46:117-21.
45. Weddington WW, Brown BS, Haertzen CA, et al. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug Alcohol Abuse. 1991; 17(2): 137-52.
46. Arndt IO, McLellan AT, Dorozynsky L, et al. Desipramine treatment for cocaine dependence. J Nerv Ment Dis. 1994; 182(3): 151-6.
47. Berger P, Watson S, Akii H, et al. The effects of naloxone in chronic schizophrenia. Am J Psychiatry. 1981;138:913-5.
48. Watson SJ, Berger PA, Akii H, et al. Effects of naloxone in schizophrenia: Reduction in hallucinations in a subpopulation of subjects. Science. 1978;201:73-6.
49. Janowsky DS, Judd L, Huey L, et al. Naloxone effects on manic symptoms and growth-hormone levels. Lancet. 1978;1:320.
50. Verhoeven WMA, van Praag HM, de Jong JTVM. Use of naloxone in schizophrenic psychoses and manic syndromes. Neuropsychobiology. 1981;7:159-68.
51. Emrich HM, Cording C, Piree S, et al. Indication of an antipsychotic action of the opiate antagonist naloxone. Pharmakopsychiat. 1977;10:265-70.
52. Ragheb M, Bemey S, Ban T. Naltrexone in chronic schizophrenia. Int Pharmacopsychiatry. 1980;15:1-5.
53. Simpson GM, Branchey MH, Lee JH. A trial of naltrexone in chronic schizophrenia. Curr Ther Res. 1977;22(6):909-13.
54. Mielke DH, Gaillant DM. An oral opiate antagonist in chronic schizophrenia: A pilot study. Am J Psychiatry. 1977;134:1430-1.
55. Gitlin M, Rosenblatt M. Possible withdrawal from endogenous opiates in schizophrenics. Am J Psychiatry. 1978;135(3):377-8.
56. Dysken MW, Davis JM (letter). Naloxone in amylobarbitone responsive catatonia. Br J Psychiatry. 1978;133:476-80.
57. Major LF, Lemer P, Ballenger JC, et al. Dopamine beta-hydroxylase in the cerebrospinal fluid: Relationship to disulftram-induced psychosis. Biol Psychiatry. 1979;14:337-44.
58. Kofoed L. Outpatient vs. inpatient treatment for the chronically mentally ill with substance use disorders. J Addict Dis. 1993; 12(3): 123-37.
59. Kofoed L, Kania J, Walsh T, et al. Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiatry. 1986;143: 867-72.
60. Kofoed LL. Chemical monitoring of disulfiram compliance: A study of alcoholic outpatients. Alcohol Clin Exp Res. 1987;11:481-5.
61. Britzer DA, Hartman N, Sweeney J, et al. Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. Am J Psychiatry. 1985;142:1106-7.